ID

45947

Descrizione

Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.

collegamento

dpGaP study=phs000855

Keywords

  1. 15-03-24 15-03-24 - Dr. Christian Niklas
  2. 16-03-24 16-03-24 - Madita Rudolph
Titolare del copyright

Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA

Caricato su

15 maart 2024

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

dbGaP phs000855 Resistance studies in Lung Cancer

Eligibility Criteria

Inclusion and exclusion criteria
Descrizione

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
The presence of the EML4-ALK fusion protein was confirmed by RT-PCR for all patient-derived tumors before sequencing. Tumor specimens included in the treatment-naive cohort were obtained before treatment was initiated. Tumor specimens included in the crizotinib-resistant cohort were obtained after the development of resistance to crizotinib following an initial response to crizotinib.
Descrizione

Elig.phs000855.v1.p1.1

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3499377
UMLS CUI [1,2]
C0750484
UMLS CUI [1,3]
C0599161
UMLS CUI [2,1]
C0200345
UMLS CUI [2,2]
C0332152
UMLS CUI [2,3]
C0087111
UMLS CUI [3,1]
C0200345
UMLS CUI [3,2]
C0231290
UMLS CUI [3,3]
C2974289
UMLS CUI [3,4]
C1514892

Similar models

Eligibility Criteria

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Elig.phs000855.v1.p1.1
Item
The presence of the EML4-ALK fusion protein was confirmed by RT-PCR for all patient-derived tumors before sequencing. Tumor specimens included in the treatment-naive cohort were obtained before treatment was initiated. Tumor specimens included in the crizotinib-resistant cohort were obtained after the development of resistance to crizotinib following an initial response to crizotinib.
boolean
C3499377 (UMLS CUI [1,1])
C0750484 (UMLS CUI [1,2])
C0599161 (UMLS CUI [1,3])
C0200345 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C0200345 (UMLS CUI [3,1])
C0231290 (UMLS CUI [3,2])
C2974289 (UMLS CUI [3,3])
C1514892 (UMLS CUI [3,4])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial